Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report) Director Alan Sebulsky bought 8,435 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was bought at an average cost of $27.67 per share, for a total transaction of $233,396.45. Following the acquisition, the director owned 20,935 shares of the company’s stock, valued at approximately $579,271.45. This trade represents a 67.48% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Alan Sebulsky also recently made the following trade(s):
- On Monday, June 15th, Alan Sebulsky bought 9,065 shares of Parabilis Medicines stock. The stock was bought at an average cost of $26.49 per share, for a total transaction of $240,131.85.
- On Thursday, June 11th, Alan Sebulsky bought 12,500 shares of Parabilis Medicines stock. The stock was bought at an average cost of $20.00 per share, for a total transaction of $250,000.00.
Parabilis Medicines Stock Up 6.3%
NASDAQ:PBLS opened at $26.59 on Wednesday. Parabilis Medicines, Inc. has a 12-month low of $24.51 and a 12-month high of $34.47.
Featured Stories
- Five stocks we like better than Parabilis Medicines
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
